Performance of the mtbdrsl assay in georgia

International Journal of Tuberculosis and Lung Disease

Volumn 18, Issue 2, 2014, Pages 233-239

  Tukvadze, Nestani ^a   Bablishvili, N ^a   Apsindzelashvili, R ^a   Blumberg, H M ^b   Kempker, Russell R ^b  

^a National Centre for Tuberculosis and Lung Disease   (Georgia)

^b EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Drug resistance; Line probe assays; Tuberculosis

Indexed keywords

CAPREOMYCIN; KANAMYCIN; OFLOXACIN;

ACID FAST BACTERIUM; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; ASSAY; BACTERIUM CULTURE; BACTERIUM ISOLATE; CONTROLLED STUDY; DIAGNOSTIC EQUIPMENT; DIAGNOSTIC TEST ACCURACY STUDY; EXTENSIVELY DRUG RESISTANT TUBERCULOSIS; HUMAN; INTERMETHOD COMPARISON; LINE PROBE ASSAY; MAJOR CLINICAL STUDY; MOLECULAR DIAGNOSTICS; MULTIDRUG RESISTANT TUBERCULOSIS; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY; SPUTUM ANALYSIS; UNITED STATES;

ANTITUBERCULAR AGENTS; CAPREOMYCIN; DRUG RESISTANCE, MULTIPLE, BACTERIAL; EXTENSIVELY DRUG-RESISTANT TUBERCULOSIS; FEASIBILITY STUDIES; GEORGIA (REPUBLIC); HUMANS; KANAMYCIN; MICROBIAL SENSITIVITY TESTS; MOLECULAR DIAGNOSTIC TECHNIQUES; MYCOBACTERIUM TUBERCULOSIS; OFLOXACIN; PREDICTIVE VALUE OF TESTS; REPRODUCIBILITY OF RESULTS; SPUTUM; TUBERCULOSIS, MULTIDRUG-RESISTANT; TUBERCULOSIS, PULMONARY; WORKFLOW;

EID: 84892594825     PISSN: 10273719     EISSN: None     Source Type: Journal    
DOI: 10.5588/ijtld.13.0468     Document Type: Article

References (27)

1. World Health Organization. Global tuberculosis control: WHO report 2012.WHO/HTM/2012.6. Geneva, Switzerland: WHO, 2012
2. Abubakar I, Zignol M, Falzon D, et al. Drug-resistant tuberculosis: time for visionary political leadership. Lancet Infect Dis 2013; 13: 529-539
3. Raviglione M. XDR-TB: entering the post-antibiotic era? Int J Tuberc Lung Dis 2006;10:1185-1187
4. Tukvadze N, Kempker R R, Kalandadze I, et al. Use of a molecular diagnostic test in AFB smear-positive tuberculosis suspects greatly reduces time to detection of multidrug- resistanttuberculosis. PLOS ONE 2012; 7: e31563
5. World Health Organization. The use of molecular line probe assay for the detection of resistance to second-line antit uberculosis drugs: expert group meeting report, February 2013. WHO/HTM/TB/2013.01. Geneva, Switzerland: WHO, 2013
6. Richards D C, Mikiashvili T, Parris J J, et al. High prevalence of hepatitis C virus but not HIV co-infection among patients with tuberculosis in Georgia. Int J Tuberc Lung Dis 2006;10: 396-401
7. Parsons L M, Somoskovi A, Gutierrez C, et al. Laboratory diagnosis of tuberculosis in resource-poor countries: challenges and opportunities. Clin Microbiol Rev 2011; 24: 314-350
8. World Health Organization. Guidelines for surveillance of drug resistance in tuberculosis. 4th ed. WHO/HTM/TB/2009.422. Geneva, Switzerland: WHO, 2009
9. World Health Organization. Policy guidance on drug susceptibility testing (DST) of second-line anti-tuberculosis drugs. WHO/HTM/TB/2008.392. Geneva, Switzerland:WHO,2008
10. Harris P A, Taylor R, Thielke R, Payne J, Gonzalez N, Conde J G. Research electronic data capture (REDCap) - a metadatadriven methodology and workfl ow process for providing translational research informatics support. J Biomed Inform 2009; 42: 377-381
11. Feng Y, Liu S, Wang Q, et al. Rapid diagnosis of drug resistance to fl uoroquinolones, amikacin, capreomycin, kanamycin and ethambutol using genotype MTBDRsl assay: a meta-analysis. PLOS ONE 2013; 8: e55292
12. Kontsevaya I, Ignatyeva O, Nikolayevskyy V, et al. Diagnostic accuracy of the genotype MTBDRsl assay for rapid diagnosis of extensively drug-resistant tuberculosis in HIV-coinfected patients. J Clin Microbiol 2013; 51: 243-248
13. Lacoma A, Garcia-Sierra N, Prat C, et al. GenoType MTBDRsl for molecular detection of second-line-drug and ethambutol resistance in Mycobacterium tuberculosis strains and clinical samples. J Clin Microbiol 2012; 50: 30-36
14. Hillemann D, Rüsch-Gerdes S, Richter E. Feasibility of the GenoType MTBDRsl assay for fl uoroquinolone, amikacinc apreomycin, and ethambutol resistance testing of Mycobacterium tuberculosis strains and clinical specimens. J Clin Microbiol 2009;47:1767-1772
15. Miotto P, Cabibbe A M, Mantegani P, et al. GenoType MTBDRsl performance on clinical samples with diverse genetic background. Eur Respir J 2012; 40: 690-698
16. Barnard M, Warren R, Van Pittius N G, et al. Genotype MTBDRsl line-probe assay shortens time to diagnosis of extensively drug-resistant tuberculosis in a high-throughput diagnostic laboratory. Am J Respir Crit Care Med 2012; 186: 1298-1305
17. Chihota V N, Muller B, Mlambo C K, et al. Population structure of multi- and extensively drug-resistant Mycobacterium tuberculosis strains in South Africa. J Clin Microbiol 2012; 50: 995-1002
18. Georghiou S B, Magana M, Garfein R S, Catanzaro D G, C atanzaro A, Rodwell T C.Evaluation of genetic mutations associated with Mycobacterium tuberculosis resistance to amikacin, kanamycin and capreomycin: a systematic review. PLOSONE 2012; 7:e33275
19. Huang W L, Chi T L, Wu M H, Jou R. Performance assessment of the GenoType MTBDRsl test and DNA sequencing for detection of second-line and ethambutol drug resistance among patients infected with multidrug-resistant Mycobacterium tuberculosis. J Clin Microbiol 2011; 49: 2502-2508
20. Casali N, Nikolayevskyy V, Balabanova Y, et al. Microevolution of extensively drug- resistant tuberculosis in Russia. Genome Res 2012; 22: 735-745
21. Gikalo M B, Nosova E Y, Krylova L Y, Moroz A M. The role of eis mutations in the development of kanamycin resistance in Mycobacterium tuberculosis isolates from the Moscow region. J Antimicrob Chemother 2012; 67: 2107-2109
22. Niemann S, Diel R, Khechinashvili G, Gegia M, Mdivani N, Tang Y W. Mycobacterium tuberculosis Beijing lineage favors the spread of multidrug-resistant tuberculosis in the Republic of Georgia. J Clin Microbiol 2010; 48: 3544-3550
23. Wells W A, Boehme C C, Cobelens F G, et al. Alignment of new tuberculosis drug regimens and drug susceptibility testing: a framework for action. Lancet Infect Dis 2013;13: 449-458
24. Streicher E M, Bergval I, Dheda K, et al. Mycobacterium tuberculosis population structure determines the outcome of geneticsbased second-line drug resistance testing. Antimicrob Agents Chemother 2012; 56: 2420-2427
25. Folkvardsen D B, Svensson E, Thomsen V O, et al. Can molecular methods detect 1% isoniazid resistance in Mycobacterium tuberculosis? J Clin Microbiol 2013; 51: 1596-1599
26. Horne D J, Pinto L M, Arentz M, et al. Diagnostic accuracy and reproducibility of WHO-endorsed phenotypic drug susceptibility testing methods for fi rst-line and second- line antituberculosis drugs. J Clin Microbiol 2013; 51: 393-401
27. Kim S J, Espinal M A, Abe C, et al. Is second-line antit uberculosis drug susceptibility testing reliable? Int J Tuberc Lung Dis 2004; 8: 1157-1158